RT Journal Article
SR Electronic
T1 Population-based seroprevalence of SARS-CoV-2 is more than halfway through the herd immunity threshold in the State of Maranhão, Brazil
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.28.20180463
DO 10.1101/2020.08.28.20180463
A1 Silva, Antônio Augusto Moura da
A1 Lima-Neto, Lídio Gonçalves
A1 Azevedo, Conceição de Maria Pedrozo e Silva de
A1 Costa, Léa Márcia Melo da
A1 Bragança, Maylla Luana Barbosa Martins
A1 Filho, Allan Kardec Duailibe Barros
A1 Wittlin, Bernardo Bastos
A1 Souza, Bruno Feres
A1 Oliveira, Bruno Luciano Carneiro Alves de
A1 Carvalho, Carolina Abreu de
A1 Thomaz, Erika Barbara Abreu Fonseca
A1 Simões-Neto, Eudes Alves
A1 Leite Júnior, Jamesson Ferreira
A1 Cosme, Lécia Maria Sousa Santos
A1 Campos, Marcos Adriano Garcia
A1 Queiroz, Rejane Christine de Sousa
A1 Costa, Sérgio Souza
A1 Carvalho, Vitória Abreu de
A1 Simões, Vanda Maria Ferreira
A1 Alves, Maria Teresa Seabra Soares de Brito e
A1 Santos, Alcione Miranda dos
YR 2020
UL http://medrxiv.org/content/early/2020/09/01/2020.08.28.20180463.abstract
AB Background Few population-based studies on the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been performed to date, and most of them have used lateral flow immunoassays with finger-prick, which may yield false-negative results and thus underestimate the true infection rate.Methods A population-based household survey was performed in the State of Maranhão, Brazil, from 27 July 2020 to 8 August 2020 to estimate the seroprevalence of SARS-CoV-2 using a serum testing electrochemiluminescence immunoassay. A three-stage cluster sampling stratified by four state regions was used. The estimates took clustering, stratification, and non-response into account. Qualitative detection of IgM and IgG antibodies was performed in a fully-automated Elecsys® Anti-SARS-CoV-2 electrochemiluminescence immunoassay on the Cobas® e601 analyser (Roche Diagnostics).Findings A total of 3156 individuals were interviewed. Seroprevalence of total antibodies against SARS-CoV-2 was 40·4% (95%CI 35·6-45·3). Population adherence to non-pharmaceutical interventions was higher at the beginning of the pandemic than in the last month. SARS-CoV-2 infection rates were significantly lower among mask wearers and among those who maintained social and physical distancing in the last month compared to their counterparts. Among the infected, 62·2% had more than three symptoms, 11·1% had one or two symptoms, and 26·0% were asymptomatic. The infection fatality rate was 0·17%, higher for males and advanced age groups. The ratio of estimated infections to reported cases was 22·2.Interpretation To the best of our knowledge, the seroprevalence of SARS-CoV-2 estimated in this population-based survey was the highest and the closest to the herd immunity threshold reported to date. Our results suggest that the herd immunity threshold is not as low as 20%, but at least higher than or equal to around 40%. The infection fatality rate was one of the lowest reported so far, and the proportion of asymptomatic cases was low.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe funder facilitated data acquisition and helped in the analysis, interpretation, and writing. The corresponding author confirms that he had full access to all the data in the study and had the final responsibility for the decision to submit for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Research Ethics Committee of the Carlos Macieira Hospital of the Maranhao State Health Secretariat under CAAE number 34708620.2.0000.8907. Written informed consent was provided by the participants or the parents/legal guardians.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe can share the data if requested by the journal.